Want to see REVB full AI Analyst Report?
REVB Stock Chart & Stats
$1.06
$0.04(3.50%)
At close: 4:00 PM EDT
$1.06
$0.04(3.50%)
Day’s Range― - ―
52-Week Range$0.88 - $11.72
Previous CloseN/A
Volume6.03K
Average Volume (3M)740.56K
Market Cap
$4.06M
Enterprise Value-$9.51
Total Cash (Recent Filing)$14.11M
Total Debt (Recent Filing)$759.04K
Price to Earnings (P/E)―
Beta0.60
Next Earnings
Aug 07, 2026EPS Estimate
-0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.14
Shares Outstanding3,908,420
10 Day Avg. Volume239,834
30 Day Avg. Volume740,557
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.22
Price to Sales (P/S)0.00
P/FCF Ratio-0.24
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$16.00Price Target Upside1409.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-5
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage & Higher EquityA low debt-to-equity ratio and a material increase in equity improve financial flexibility for a clinical-stage biotech. This reduces near-term refinancing risk, gives the company more runway to fund R&D without excessive leverage, and supports durability through development cycles.
Stronger Executive Contracts & Board OversightLonger-term executive contracts, enhanced change-in-control protections, and a newly elected director increase leadership continuity. For a clinical-stage company with multi-year development timelines, stable management and governance reduce execution risk and aid consistent R&D strategy execution.
Adopted Shareholder Rights PlanA rights plan can protect the company from opportunistic takeovers that might disrupt long-term scientific programs. By preserving negotiating leverage, the board safeguards strategic decision-making and the ability to pursue development milestones without forced, short-term deal pressure.
Bears Say
No Revenue GenerationOperating without any commercial revenue leaves the company fully reliant on financing and partnerships to fund operations. For a clinical-stage biotech, this creates structural funding dependency and elevates execution risk until clinical success translates into sustainable revenue streams.
Persistent Cash BurnSustained negative operating and free cash flow requires ongoing external capital, which can dilute shareholders or constrain development if markets tighten. Although cash outflows improved versus 2024, the company still needs a durable funding plan to complete trials and advance its pipeline.
Wide Reverse-split AuthorizationAuthorization of a broad reverse-split range signals underlying capitalization or listing pressure and creates a structural overhang. If exercised, a reverse split can reduce liquidity, harm investor perception, and reflect persistent share-price/listing risks that complicate long-term capital access.
Revelation Biosciences News
REVB FAQ
What was Revelation Biosciences’s price range in the past 12 months?
Revelation Biosciences lowest stock price was $0.88 and its highest was $11.72 in the past 12 months.
What is Revelation Biosciences’s market cap?
Revelation Biosciences’s market cap is $4.06M.
When is Revelation Biosciences’s upcoming earnings report date?
Revelation Biosciences’s upcoming earnings report date is Aug 07, 2026 which is in 7 days.
How were Revelation Biosciences’s earnings last quarter?
Revelation Biosciences released its earnings results on May 07, 2026. The company reported -$2.71 earnings per share for the quarter, the consensus estimate of -$2.71 by $0.
Is Revelation Biosciences overvalued?
According to Wall Street analysts Revelation Biosciences’s price is currently Undervalued.
Does Revelation Biosciences pay dividends?
Revelation Biosciences does not currently pay dividends.
What is Revelation Biosciences’s EPS estimate?
Revelation Biosciences’s EPS estimate is -0.83.
How many shares outstanding does Revelation Biosciences have?
Revelation Biosciences has 3,908,420 shares outstanding.
What happened to Revelation Biosciences’s price movement after its last earnings report?
Revelation Biosciences reported an EPS of -$2.71 in its last earnings report, expectations of -$2.71. Following the earnings report the stock price went down -5.882%.
Which hedge fund is a major shareholder of Revelation Biosciences?
Currently, no hedge funds are holding shares in REVB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Revelation Biosciences
Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.
REVB Stock 12 Month Forecast
Average Price Target
$16.00
▲(1409.43% Upside)
Technical Analysis
GT Biopharma
―
Dermata Therapeutics
―
CERo Therapeutics Holdings
―
Psyence Biomedical
―
Azitra Inc
―
Ownership Overview
8.82% Insiders
0.69% Mutual Funds
10.81% Other Institutional Investors
79.68% Public Companies and
Individual Investors